Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04627077 · ClinicalTrials.gov registry record
Livestrong Cancer Institutes' Patient Reported Outcomes Study
A clinical trial of Neoplasms and Drug Therapy, sponsored by University of Texas at Austin.
- Completed
- Registry status
- 121
- Enrollment target
- 1
- Study location
NCT04627077 is a study of Neoplasms and Drug Therapy that has completed, run by University of Texas at Austin. The registered enrollment target is 121 participants, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04627077, a study of Neoplasms and Drug Therapy, has completed, sponsored by University of Texas at Austin.
- COMPLETED
- Registry status
- 121 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study will be to collect baseline patient reported outcome measures at the Livestrong Cancer Institutes (LCI) with the goal of improving quality care and to inform decision making by patients, providers, and researchers for future LCI initiatives.
Conditions Studied
Study Locations (1)
Texas
- Dell Seton Medical Center - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2018-01-22 |
| Est. Completion | 2019-01-25 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04627077
The ClinicalTrials.gov registry entry for NCT04627077 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (93% lower). The listed sponsor is University of Texas at Austin, which has 257 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Neoplasms appearing as the primary indexed condition, and to 0 interventions.
NCT04627077 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT04627077 about?
NCT04627077 is a clinical study titled "Livestrong Cancer Institutes' Patient Reported Outcomes Study". The goal of this study will be to collect baseline patient reported outcome measures at the Livestrong Cancer Institutes (LCI) with the goal of improving quality care and to inform decision making by patients, providers, and researchers for future LCI initiatives.
What is the current status of trial NCT04627077?
This trial is currently completed. The enrollment target is 121 participants. The study started on 2018-01-22. Estimated completion is 2019-01-25.
What conditions does trial NCT04627077 study?
This clinical trial studies the following conditions: Neoplasms, Drug Therapy.
Who is sponsoring clinical trial NCT04627077?
This trial is sponsored by University of Texas at Austin, which has 257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04627077 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
RECRUITING · Phase 1
-
Real World Registry for Use of the Ion Endoluminal System
RECRUITING
-
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
RECRUITING · Phase 1
-
Endometrial Cell Collection With the PadKit
RECRUITING · NA
-
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
RECRUITING · Phase 1
-
Resilience in East Asian Immigrants for Advance Care Planning Discussions
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.